Mechanisms of SARS-CoV-2 entry into cells

CB Jackson, M Farzan, B Chen, H Choe - Nature reviews Molecular …, 2022 - nature.com
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The first 12 months of COVID-19: a timeline of immunological insights

T Carvalho, F Krammer, A Iwasaki - Nature Reviews Immunology, 2021 - nature.com
Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
China, in December 2019, the novel coronavirus that causes this disease—severe acute …

COVID-19: breaking down a global health crisis

SI Mallah, OK Ghorab, S Al-Salmi, OS Abdellatif… - Annals of clinical …, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

A Wajnberg, F Amanat, A Firpo, DR Altman, MJ Bailey… - Science, 2020 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …

[HTML][HTML] Map** neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

L Piccoli, YJ Park, MA Tortorici, N Czudnochowski… - Cell, 2020 - cell.com
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-
CoV-2 infection is crucial for understanding immune protection and identifying targets for …

Early outpatient treatment for Covid-19 with convalescent plasma

DJ Sullivan, KA Gebo, S Shoham… - … England Journal of …, 2022 - Mass Medical Soc
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2024 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay

A Narayanan, M Narwal, SA Majowicz… - Communications …, 2022 - nature.com
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …

Early high-titer plasma therapy to prevent severe Covid-19 in older adults

R Libster, G Pérez Marc, D Wappner… - … England Journal of …, 2021 - Mass Medical Soc
Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-
19) remain elusive. Among them, convalescent plasma administered to hospitalized patients …

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

I Monsef, C Doree, EM Wood… - Cochrane Database …, 2020 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …